Capital Research Global Investors Purchases New Position in Medline $MDLN

Capital Research Global Investors purchased a new stake in Medline (NASDAQ:MDLN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 14,784,203 shares of the company’s stock, valued at approximately $620,937,000. Capital Research Global Investors owned approximately 1.13% of Medline as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Sound Income Strategies LLC bought a new stake in shares of Medline in the 4th quarter valued at approximately $25,000. Entrust Financial LLC bought a new stake in Medline during the fourth quarter worth approximately $26,000. NBC Securities Inc. bought a new stake in Medline during the fourth quarter worth approximately $28,000. Global Retirement Partners LLC bought a new stake in Medline during the fourth quarter worth approximately $31,000. Finally, North Star Investment Management Corp. bought a new stake in Medline during the fourth quarter worth approximately $36,000.

Medline Price Performance

MDLN opened at $33.61 on Monday. Medline has a 1-year low of $32.81 and a 1-year high of $50.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 4.41 and a quick ratio of 2.51. The company has a 50 day simple moving average of $41.45.

Medline (NASDAQ:MDLN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The business had revenue of $7.35 billion during the quarter. Medline’s revenue was up 10.7% compared to the same quarter last year. Equities research analysts predict that Medline will post 1.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MDLN has been the subject of a number of recent analyst reports. Robert W. Baird decreased their target price on Medline from $57.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday. BMO Capital Markets upped their target price on Medline from $45.00 to $54.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. BNP Paribas Exane decreased their target price on Medline from $49.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, May 14th. UBS Group upped their target price on Medline from $48.00 to $57.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Barclays decreased their target price on Medline from $50.00 to $45.00 and set an “overweight” rating for the company in a research report on Monday, June 1st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $50.54.

Medline Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.